Table 1.
Characteristics of the included studies.
| Study | Study Design | Intervention Groups | Total Patients | Male Number (% of Total) | Average Age (years) | Fingers Affected a | Joints Affected b | Follow-Up Period (years) |
|---|---|---|---|---|---|---|---|---|
| [12] | RCT | CCH | 36 | 36 (100) | 69.6 | NR | 46 | 3 |
| PNF | 34 | 31 (86) | 67.2 | NR | 48 | |||
| [4] | RCT | CCH | 78 | 65 (83) | 65 (±8.1) | 78 | NR | 5 |
| PNF | 78 | 68 (87) | 65 (±9.1) | 78 | NR | |||
| [8] | Retrospective cohort | CCH | 153 | 115 (75) | 65.8 | NR | NR | 5 |
| PNF | 367 | 314 (86) | 63.8 | NR | NR | |||
| [16] | Retrospective cohort | CCH | 29 | 24 (85) | 67 (±10) | NR | 34 | 0.5 |
| PNF | 30 | 22 (75) | 66 (±10) | NR | 50 | |||
| [5] | RCT | CCH | 38 | 36 (95) | 67 | NR | 40 | 1 |
| PNF | 45 | 36 (80) | 67 | NR | 46 | |||
| [13] | RCT | CCH | 38 | 36 (95) | 67 | NR | 40 | 3 |
| PNF | 45 | 36 (80) | 67 | NR | 46 | |||
| [7] | RCT | CCH | 29 | 20 (69) | 62 (58–66) c | NR | NR | 2 |
| PNF | 21 | 17 (81) | 67 (64–70) c | NR | NR | |||
| [10] | RCT | CCH | 69 | 56 (81) | 66 | 70 | NR | 1 |
| PNF | 71 | 63 (89) | 69 | 71 | NR | |||
| [9] | RCT | CCH | 20 | 17 (85) | 65 | 20 | NR | 1 |
| PNF | 19 | 17 (89) | 67 | 19 | NR | |||
| [11] | RCT | CCH | 78 | 65 (83) | 65 | 78 | NR | 2 |
| PNF | 78 | 68 (87) | 68 | 78 | NR | |||
| [14] | Prospective observation study | CCH | 52 | 50 (96) | 71 ± 8.9 | 3.8 ± 1 1 | 2.2 ± 0.5 2 | 0.5 |
| PNF | 26 | 25 (96) | 70 ± 7.6 | 4.2 ± 0.9 1 | 2.2 ± 0.4 2 |
Abbreviations: CCH; collagenase clostridium histolyticum, NR; not reported, PNF; percutaneous needle fasciotomy, RCT; randomised controlled trial, STD; standard deviation. a Total joint involved in the treatments. b Total finger involved in the study treatments. c 95% confidence interval. 1 Total affected finger per patient (mean ± STD). 2 Total affected joints per patient (mean ± STD).